key: cord-0877228-rh8w93rs
authors: Sokolowska, Milena; Rovati, G Enrico; Diamant, Zuzana; Untersmayr, Eva; Schwarze, Jürgen; Lukasik, Zuzanna; Sava, Florentina; Angelina, Alba; Palomares, Oscar; Akdis, Cezmi; O'Mahony, Liam; Jesenak, Milos; Pfaar, Oliver; Torres, María José; Sanak, Marek; Dahlén, Sven‐Erik; Woszczek, Grzegorz
title: Effects of non‐steroidal anti‐inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID‐19
date: 2022-02-25
journal: Allergy
DOI: 10.1111/all.15258
sha: f2947098b5e96ca4d81185b59d8c4fcf84051ef0
doc_id: 877228
cord_uid: rh8w93rs

Non‐steroidal anti‐inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti‐inflammatory, antipyretic, and analgesic effects are applied against symptoms of respiratory infections, including SARS‐CoV‐2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID‐19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs‐exacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of NSAIDs in COVID‐19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID‐19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current eicosanoid research.

Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are one of the most frequently used anti-inflammatory medications worldwide against symptoms of infections, other acute and chronic inflammatory diseases, and pain.

Eicosanoids, including prostaglandins (PGs), leukotrienes (LTs), thromboxanes (TXs), hydroxyeicosatetraenoic acids (HETEs), lipoxins (LXs), and many recently proposed pro-resolving mediators constitute a wide range of active lipid mediators possessing pro-and anti-inflammatory, as well as pro-resolution properties. 1 They are products of the major unsaturated fatty acids: arachidonic acid (AA), dihomoγ-linolenic acid (DHGLA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), metabolized in three main pathways: cyclooxygenase (COX), lipoxygenase (LO or LOX), and cytochrome P450 ( Figure 1 ). Those active lipid mediators play substantial roles in the development and resolution of inflammation, including allergic and viral inflammation, which we have reviewed extensively in the previous report. 1 Even though NSAIDs and other eicosanoid pathway modifiers are so commonly consumed and are relatively safe for the majority of people, the current pandemic of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) revealed substantial knowledge gaps in understanding their modes of action, benefits, and risks related to their use in patients with respiratory and allergic diseases. Unfortunately, this resulted in the conflicting messages sent to the public from the scientific community. Therefore, we, the European Academy of Allergy and Clinical Immunology Task Force (EAACI TF) on Eicosanoids, here critically review the most recent findings on the roles of NSAIDs, leukotriene antagonists (LTRAs), prostaglandin D 2 (PGD 2 ) receptor antagonists, and cannabinoids, as well as we summarize their selectivity, and additional modes of actions in allergic airway diseases, drug allergy, and respiratory virus infections. In addition, we also describe here the effects of novel T2 biologicals used in allergic diseases on eicosanoid pathways.

Aside from NSAIDs-exacerbated respiratory disease (NERD), NSAIDs are usually well tolerated by patients with asthma, and therefore, they are often used in real life against symptoms of respiratory infection such as fever and pain, even during asthma exacerbations together with intensified asthma treatment in children and adults. 2 Current Global Initiative for Asthma (GINA) guidelines are stating with evidence level A, that aspirin and other NSAIDs are generally not contraindicated in patients with asthma, unless there is a history of previous reactions to those medications. Nevertheless, it is still not very well studied whether NSAIDs facilitate or inhibit achievement of asthma control following exacerbations, and if they affect the speed of resolution of airway inflammation. Exacerbations of asthma are most often induced by common respiratory viruses including rhinovirus (RV), respiratory syncytial virus (RSV), bocavirus, influenza viruses, adenovirus, and others. [3] [4] [5] RV is responsible for up to 76% of exacerbations of wheeze in children and up to 83% of asthma attacks in adults. [3] [4] [5] Recurrent viral infections do not only cause acute disease and exacerbations of established disease, but they also contribute to the pathophysiology of early wheezing in children and the development of asthma. Prophylaxis of RSV-induced bronchiolitis with palivizumab, an anti-RSV monoclonal antibody, in late preterm infants decreased the risk of recurrent infant wheeze and inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDsexacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of NSAIDs in COVID-19, and the role of NSAIDs in asthma and viral asthma exacerbations.

We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current eicosanoid research.

asthma, biologicals, COVID-19, LTRA, NSAID the rate of parent-reported asthma symptoms at 6 years of age, however, without any effect on lung function or doctor-diagnosed asthma. 6, 7 The majority of respiratory viruses are known to modify several major eicosanoid pathways, including the COX and the LOX pathways 8 (Figure 2 ). RV infection increases expression of 5-lipoxygenase (5-LOX), 5-lipoxygenase activating protein (FLAP), and cyclooxygenase-2 (COX-2), as well as the production of prostaglandins E 2 (PGE 2 ) and PGD 2 by the respective isomerases in human bronchial epithelial cells, with higher levels in asthmatic patients than in controls. 9 In addition, cysteinyl leukotriene (cysteinyl-LT) levels, 5-LOX-positive cells, and FLAP-positive cells in bronchoalveolar lavage fluid are increased in humans upon RV infection and correlate with the emergence of upper respiratory symptoms. 10 Infection with RV affects airway mucosal barriers and also the peripheral blood and distant tissues. PGE 2 plays an important role in optimal antibody synthesis, as COX inhibitors reduce antibody release by plasma cells, also in case of viral infections. 11, 12 Healthy individuals experimentally infected with RV showed a suppressed serum neutralizing antibody response when treated with aspirin or acetaminophen. 13 Significant increase in COX-2 (PTGS2) expression and in COX-derived metabolites is a hallmark of RSV 14 and influenza virus infection. 15 Pharmacologic inhibition of the COX pathway decreased RSV-induced lung pathology, although this was not linked to a specific metabolite. 14,16 At a later stage of RSV infection there is an increase in LOX metabolites, which might promote appropriate resolution of infection-induced F I G U R E 1 Eicosanoid biosynthesis and signaling pathways are therapeutic targets of medications used in the treatment of infections, acute and chronic inflammatory diseases (including asthma and allergy) and pain. Glucocorticosteroids (GCs), non-steroidal antiinflammatory drugs (NSAIDs), leukotriene receptor antagonists (LTRAs, e.g., montelukast, zafirlukast, pranlukast), 5-lipoxygenase (5-LOX) inhibitor, zileuton, as well as still clinically tested, timapiprant and setitpiprant act directly on the synthesis of eicosanoid mediators or their signaling molecules and receptors. Biosynthesis of endocannabinoids (2-AG, AEA) interfere with eicosanoids metabolic pathways. 2-AG-2-Arachidonoyl-glycerol (endocannabinoid); AEA-arachidonyl-ethanolamide (endocannabinoid); COX-cyclooxygenase; Cyt-cytochrome; EET-epoxyeicosatrienoic acid; GC-glucocorticoids; HETE-hydroxyeicosatetraenoic acid; HPETE-hydroperoxyeicosatetraenoic acid; LOX-lipoxygenase; LTE 4 -leukotriene; LTRA-leukotriene receptor antagonists; LX-lipoxin; PLA-phospholipase; PG-prostaglandin; and TX-thromboxane NLRP3 inflammasome activation can contribute to limiting viral replication at the early stages of infection, but in some instances, it may also lead to harmful hyperinflammation during late-stage infection. 19 Much less is known about PGD 2 and antiviral responses.

However, it was shown that in aging mice there is an increase in 

NSAIDs are used worldwide to alleviate symptoms of viral infections and inflammation, such as fever, cough, and pain. Since NSAIDs inhibit COX-1 and COX-2 and thus decrease the release of many downstream lipid mediators, such as various PGs, prostacyclin, and TXs, they have very broad effects on inflammation and immune responses, ranging from anti-inflammatory, immunosuppressive, and anti-thrombotic to pro-resolving ( Figure 2 ). 1, 21 Therefore, at the beginning of the COVID-19 pandemic, there were several concerns and uncertainties about the effects of NSAIDs on SARS-CoV-2 infection and the course of COVID-19. 22 They were suspected to alter the expression of angiotensin-converting enzyme 2 (ACE2), the main entry receptor for SARS-CoV-2 and/or modify viral replication. [23] [24] [25] [26] In addition, they could be either harmful by impairing antiviral response and delaying resolution of inflammation 15, 18, 27, 28 or be beneficial by dampening of hyperinflammation and cytokine storm 29, 30 and preventing thrombosis 31 or meloxicam (more selective COX-2 inhibitor) did not change the expression of ACE2 in human cell lines (Calu-3 or Huh7.5) in vitro or in lungs, kidney, heart, or ileum of mice in vivo. 33 Similarly, both

NSAIDs did not affect SARS-CoV-2 entry or its replication in the same human cell lines. 33 Aspirin also did not affect ACE2 or transmembrane serine protease 2 (TMPRSS2) expression in human nasal epithelium. 36 Meloxicam also did not prevent SARS-CoV-2-infectioninduced weight loss in mice and did not change frequencies or activations status of alveolar macrophages, neutrophils, NK cells, Ly6C+

Mo/Mθ, CD4 + T cells, CD8 + T cells, and γδ T cells. However, meloxicam treatment decreased the amount of spike-specific IgM and IgG antibodies and their neutralizing capacities as well as decreased infection-induced levels of IL-6, CCL2, GM-CSF, CXCL10, IL-2, and TNFα, suggesting that while meloxicam can impair humoral immune response against SARS-CoV-2 to some extent, it might also limit levels of proinflammatory cytokines. 33 In contrast, naproxen, which is a non-selective COX-1/COX-2 inhibitor, has been shown to bind to the nucleocapsid protein N of SARS-CoV-2, which led to inhibition of SARS-CoV-2 replication in VeroE6 cells and primary human bronchial epithelial cells and protected epithelium against SARS-CoV-2-induced barrier damage. 37 There were no analogous effects in similar experiments with paracetamol (acetaminophen, which may affect PG production in the brain or may act via its metabolite on the cannabinoid receptors), 38, 39 or celecoxib (selective COX-2 inhibitor). 37 Naproxen is currently examined in the clinical trial in COVID-19

Non-steroidal anti-inflammatory drugs and leukotriene antagonists in SARS-CoV-2 infection. Increased levels of eicosanoids have been found in bronchoalveolar lavage fluid of patients with severe COVID-19, with predominance of prostaglandins and thromboxane. There are strong grounds to explore eicosanoid inhibition as a potential therapeutic target in SARS-CoV-2 infections. Prostaglandins amplify innate immune responses to pathogen-and damage-associated molecular patterns, enhance the cascade of proinflammatory cytokine release, activate Th1 and Th17 cells, and contribute to recruitment of macrophages and T cells. Moreover, studies in mouse adapted to SARS-CoV-2 infection showed that PGD 2 inhibition protected from severe disease. Despite the initial mixed reports on the use of NSAIDs in COVID-19, it has been concluded that these medications can be safely used to alleviate the symptoms of SARS-CoV-2 infection. This effect is attributed to the disruption of inflammatory circuits. Other effects of NSAIDs in COVID-19 are being investigated, and preliminary studies suggest that a non-selective NSAID naproxen could negatively influence SARS-CoV-2 replication. Furthermore, the efficacy of leukotriene antagonist montelukast is being evaluated in a series of clinical trials. The hypothesized mode of action in COVID-19 includes inhibition of leukotriene signaling, as well as direct antiviral effect (damage to the viral lipid membrane and genome), as reported for other viruses (eudract_number:2020-001301-23; accessed 11.06.2021). So far, in various patient groups, it has been shown that usage of NSAIDs does not lead to the worse COVID-19 outcomes. 40 In a retrospective study of 403 confirmed cases of COVID-19, there were no differences in terms of mortality rate or need for respiratory support between patients who were taking ibuprofen or those who did not take any NSAIDs. 41 It was also confirmed in the large prospective cohorts that either acute or chronic use of NSAIDs was not associated with worse COVID-19 outcomes. [42] [43] [44] It was even shown that in patients, who were treated with aspirin or other NSAIDs due to the cardiovascular diseases, positive aspects of such therapies have been noted, including reduction of COVID-19 mortality. 31 This clinical observation is further supported by a study on COX-2 induction and PGE 2 overproduction in the human lung infected by SARS-CoV-2. 45 However, further basic in vitro, in vivo, and large clinical studies assessing the influence of NSAIDs on the pathogenesis and treatment of COVID-19 are still greatly needed.

All clinically available LTRAs (montelukast, zafirlukast, and pranlukast) act on the cysteinyl leukotriene type 1 receptor (CysLT 1 ) and by competitive antagonism at this receptor are believed to be responsible for the control of airway inflammation, bronchoconstriction, and remodeling. [46] [47] [48] However, anti-inflammatory activity of LTRAs independent of CysLT 1 antagonism has been suggested. LTRAs reduced the eosinophil protease activity 49 and inhibited TNFα-50 or UDP-mediated 51,52 cytokine expression, as well as NF-κB activation in human mononuclear 53 or epithelial cells 54 through processes that appear to be distinct from CysLT 1 antagonism. Although mechanisms of these non-CysLT 1 -related LTRA activities are not fully understood, concentration-dependent inhibition of distinct receptors such as P2Y1, P2Y2, P2Y6, and GPR17 by LTRAs have been reported, 51, 52, 55 suggesting, at least for P2Y receptor, a noncompetitive mechanism of action. Interestingly, it was also shown that LTRAs may have a potent inhibitory effect on 5-LOX activity (i.e., LT production) 52,56 and transport of LTs by the multidrug resistance protein ABCC4, 57 suggesting a much broader mechanism of action for these drugs than previously suspected. Indeed, non- LTRAs, the most plausible biomarker that could potentially serve as response predictor to LTRAs seems LTE 4 production. Urinary LTE 4 (uLTE 4 ) is a biomarker of total body cysteinyl-LT production, 1 associated with Type 2 asthma, asthma severity, exacerbations, and NERD. 68, 69 Increased uLTE 4 to fractional exhaled nitric oxide (LTE 4 :

Fe NO ) ratio has been suggested to predict favorable response to LTRA therapy (montelukast) in asthmatic children, 70,71 but these observations have not been confirmed in adult patients. There is a considerable amount of evidence supporting the concept that some patients or clinical phenotypes seem sensitive to LTRAs, especially in a real-life setting, due to enhanced cysteinyl-LT production, better adherence to oral therapy or oral drug delivery. LTRAs have proven to be particularly effective in exercise-induced asthma, 72 asthma associated with allergic rhinitis, 73 NERD, 74 viral-induced wheezing episodes, 75 and patients having difficulties with inhaled therapy such as children and elderly. 76, 77 Cigarette smoking while inhibiting steroid anti-inflammatory responses 78 increases cysteinyl-LT production, 79 leading to a greater response to montelukast in smokers with asthma, suggesting that LTRA could be more effective in treating such individuals. 80 In fact, asthmatic patients with smoking history above 11 pack-years showed more benefit with montelukast treatment than inhaled steroids. 81 Obesity is another potential risk factor for asthma development and efficacy of treatment. Interestingly, higher body mass index (BMI) is associated with increased LT production in asthmatics 82 and as therapeutic response to inhaled corticosteroids decreases with increasing BMI, response to montelukast remains unaffected, 83 suggesting LTRA therapy to be more effective in obese patients. The response to LTRA may also be associated with sex differences. The existence of a sex bias in LT biology is already suggested by the fact that many LT-related diseases including asthma, allergic rhinitis, rheumatoid arthritis, or NERD have a higher occurrence in women compared to men, pointing to more pronounced pathophysiological roles of LTs in females. 84, 85 Furthermore, several observations suggest that female sex is associated with higher LT biosynthesis, while androgens seem to exert a suppressing role on LT formation both in vitro and in vivo. [86] [87] [88] [89] [90] Although the clinical significance of these data is still to be confirmed, in a small prospective cohort study, montelukast showed superior effects on symptoms and lung function in women compared to men, 91 while a tendency for a better response to montelukast was evident in girls exposed to tobacco smoke. 117, 118 In two proof-of-concept studies in (unphenotyped) allergic asthmatics, DP2 (CRTH2) antagonists (timapiprant and setipiprant, respectively) showed only modest reduction (approx. 25%) in the allergen-induced LAR 119, 120 while no convincing effects were observed on the allergen-induced changes in T2 biomarkers (blood eosinophils, FeNO) 120 with only a minimal reduction in sputum eosinophils post-allergen. 119 In addition, there was no decrease in the EAR in either study. The (relative) lack of protection against allergen-induced airway responses may (partly) consist with the fact that even with effective DP2-blockade, an allergen-triggered mast cell (lacking DP2) 121 mediator release (histamine, PGD 2 , cysteinyl-LTs) may still occur which is capable of causing an EAR and/or an LAR 122,123 and therefore, especially in allergic asthma, a combined blockade of, for example, DP2 ± DP1 ± TP ± cysteinyl-LT-R might provide a superior protection.

In line with this reasoning-and despite prior evidence of superior efficacy in phase 2B studies of patients with an allergic (T2-) profile (atopy ± eosinophils ≥250/mcL) 124,125 -several DP2 (CRTH2)

antagonists (e.g., setipiprant, fevipiprant) failed in phase 3 clinical trials of allergic airway disease. 125 More recently, DP2-blockade has been associated with the reduction in airway smooth muscle mass by decreasing airway eosinophilia and the recruitment of myofibroblasts and fibrocytes. 126 Therefore, with several clinical trials still ongoing, (add-on) DP2-blockade may show efficacy in more severe T2 asthma 127 and related conditions based on its anti-inflammatory and disease-modifying potential. 126, 128 Respiratory viruses (e.g., RSV) represent other important triggers of chronic inflammatory airway disease capable of activating the PGD 2 /DP2 receptor-mediated pathway, thereby eliciting a "non-allergen-induced" T2-immune response through airway epithelial cells and innate immune cells. 129 Indeed, RSV has been associated with upregulation of the PGD 2 /DP2 pathway and increased PGD 2 levels both in experimental and in clinical studies, while DP2blockade alone or combined with DP1 agonism showed protective potential in preclinical studies. 130 Therefore, selective targeting of PGD 2 receptors has been postulated to protect against respiratory viral infections, and more recently, including SARS-CoV-2. 131 Presently, this hypothesis awaits clinical evidence. In addition, the potent bronchoconstrictive actions of PGD 2 and other constrictive prostanoids in human airways call for trials with TP receptor antagonists in patients with asthma 132

The human endogenous cannabinoid system (ECS) is involved in many physiological processes. It consists of the cannabinoid re- NSAIDs that inhibit COX2 also enhance endocannabinoid levels and reduce AEA-and 2-AG-derived prostaglandins. 139, 140 In addition, some NSAIDs such as ibuprofen can influence the endocannabinoid levels by inhibiting FAAH (Figure 4) .

The role of cannabinoids in allergic diseases is still a bit controversial. 141 Sukawara et al demonstrated that endocannabinoids limited mast cell maturation and activation in human airway mucosa and skin through CB1. 142, 143 Tetrahydrocannabinol (THC) and cannabidiol (CBD) attenuated airway allergic inflammation, decreased cytokine production, cell infiltration, mucus secretion, and bronchial hyperresponsiveness in mice. [144] [145] [146] Similarly, the synthetic agonist CP55,940 induced lung protection in ovalbumine (OVA)-induced asthma guinea pig models via CB1 and CB2. 147 In keratinocytes, CB1 prevented transepithelial water loss and skin inflammation, cell infiltration and cytokine production in atopic dermatitis mouse model. 148 Anandamide and different CB1 agonists also accelerated skin barrier recovery and reduced proinflammatory cytokine production and cell recruitment. 149, 150 Several cannabinoids have also shown a protective role in allergic contact dermatitis by reducing inflammatory responses. [151] [152] [153] CB1 activation may also induce bronchodilation in the airways. 147, 154 In human bronchial epithelial cells, the synthetic agonist WIN55212-2 restored the epithelial barrier disruption induced by RV. 155 In addition, WIN55212-2 decreased the immediate anaphylactic reaction in a mouse model of peanut allergy and promoted the generation of allergen-specific regulatory T cells. 156 Currently, different studies suggest the therapeutic potential of cannabinoids in COVID-19 pandemic. [157] [158] [159] In contrast, Frei et al showed that CB2 activation enhanced migratory responsiveness of eosinophils in an OVA-asthma mouse models. 160 Accordingly, the lack of CB2 decreased allergic inflammation in asthma and dermatitis mouse model. 161 This result correlated with increased number of NK cells and reduced number of ILC2s in the lung of CB2 knockout mice, demonstrating that NK cells are negative regulators of ILC2s. 162 Interestingly, it has been described that mRNA expression levels of CB1 are upregulated in tonsils and peripheral blood of patients with allergic rhinitis, atopic dermatitis, and food allergy, but the functional relevance remains unknown. 163 These studies suggest that the ECS could be explored as a potential therapeutic target in the treatment of asthma, allergic and skin diseases, and viral infections.

Ample evidence from clinical trials showing effectiveness of drugs targeting T2-inflammation (targets include IgE and the cytokines IL5, IL4, and IL13) on asthma exacerbations, as well as improvements in symptoms and disease severity in chronic rhinosinusitis with nasal polyps (CRSwNP), 164, 165 underscored the involvement of T2-inflammation in these conditions. 166, 167 As mentioned above, the majority of asthma exacerbations are precipitated by respiratory viruses (esp. RSV and RV), 168 while in sensitized subjects, allergen exposure may enhance virally triggered exacerbations due to synergistic interaction through joint mechanisms including the T2-inflammatory pathway. [168] [169] [170] [171] Both viral and allergen-triggered pathways include several inflammatory and immune (effector) cells, such as mast cells, basophils, Th2 cells, ILCs, macrophages, neutrophils, and eosinophils. Many of these cells are capable of releasing eicosanoids upon activation and/or possess one or more eicosanoid receptors, 172 thus contributing to the exacerbation and its sequelae (e.g., bronchoconstriction, airway inflammation, and bronchial hyperresponsiveness). 173 In CRSwNP, the T2-inflammatory pathway is also triggered by several stimuli such as viruses, bacteria, and allergens, which stimulate inflammatory cell-and cytokine-mediated pathomechanisms in the nasal and paranasal mucosa. 167 Although in vitro data indicate that biologicals may influence eicosanoid pathways in mast cells and basophils, 174 

NERD, also called AERD-aspirin-exacerbated respiratory disease or AIA-aspirin-intolerant asthma, is a phenotype of asthma recognized in 5 to 25% asthmatics. It is characterized by a non-immunological (Table 1) . Diclophenac, ketorolac, ibuprofen, naproxen, indomethacin, or pyrazolone derivatives inhibit both COX-2 and COX-1, 191 therefore are contraindicated in NERD.

Acetylsalicylic acid is more potent inhibitor of COX-1 than COX-2. 189, 192 This was the first NSAID ever reported to trigger symptoms in asthmatics. Paracetamol (acetaminophen), with an unclear effects on prostanoids biosynthesis including possible inactivation of brain cyclooxygenases by a non-substrate mechanism, is tolerated by the vast majority of NERD patients unless given in very high doses. 39

Effect of biologicals used in the treatment of allergic diseases on eicosanoid pathways. Biologicals have revolutionized therapeutic algorithms for patients with the most severe form of allergic diseases. Currently, 5 monoclonal antibodies have been approved for the treatment of severe asthma. Their use has been associated with a decrease in the concentration of proinflammatory lipid mediators. This is most probably an indirect effect of inhibition of immune cells which are the main eicosanoid producers in allergic inflammation. Omalizumab (anti-IgE) binds to free IgE and inhibits their binding to IgE receptors, which results in a downregulation of FcεRI expression on mast cells, basophils, and dendritic cells. This leads to a significant decrease in biosynthesis and release of proinflammatory eicosanoids from these cells, and prevents expansion of eosinophils and ILC2. Dupilumab (anti-IL-4Rα) binds to the α subunit of the IL-4 receptor, which is shared by IL-4 and IL-13 receptor complexes. Therefore it blocks the effect of these cytokines on cells contributing to type 2 immune reaction. This results in an inhibition of IgE production, mast cell activation and eicosanoid production, goblet cell metaplasia, and mucus production. Mepolizumab, reslizumab (anti-IL-5), and benralizumab (anti-IL-5Rα) block IL-5 activity on different levels, therefore inhibiting the maturation, activation, and proliferation of eosinophils, as well as basophil activation. Monoclonal antibodies targeting IL-5Rα moreover lead to antibody-dependent cell-mediated cytotoxicity of NK cells against eosinophils and basophils, vast producers of proinflammatory eicosanoids such as prostaglandin D 2 and cysteinyl leukotrienes. While no direct effect of biologicals on eicosanoid biosynthesis has been reported, these medicines disrupt the cascade of immune events leading to type 2 inflammatory responses and the concomitant overproduction of proinflammatory lipid mediators Most of the information available on the role of eicosanoids in allergy and related diseases concerns NERD. 193, 194 This fact can be explained because it was the first clinical phenotype in which a link between NSAIDs pharmacological activity and the inhibition of PGE 2 synthesis by blocking COX-1 and the subsequent increase in cysteinyl-LTs release was established. 195 Nevertheless, some data are also available for cutaneous NSAID-induced cross-hypersensitivity. Thus, increased LTE 4 and 9α,11β-PGF 2 urinary levels have been described for NERD [196] [197] [198] [199] This consensus report summarizes up to date knowledge in this complex area and identifies major knowledge gaps and unmet needs to be addressed in the future.

• Assessment of NSAIDs role in alleviating symptoms of viral infections in general population and in patients with asthma/ allergy with the strong emphasis on the timing of its administration, their selectivity, and long-term effects.

• Further basic in vitro, in vivo, and large clinical studies assessing NSAIDs influence on the pathogenesis and treatment of COVID-19 are greatly needed.

• Understanding molecular and cellular mechanisms of eicosanoids activity in immune response with focus on balance between proand anti-inflammatory properties.

• Characterization of emerging sub-phenotypes, and sub-endotypes of allergic diseases (asthma, rhinitis, and NERD) and potential biomarkers for the more effective therapy using eicosanoid pathway modifying drugs (NSAIDs, LTRA, and CRTH2 antagonists)

• Evaluation of how the effectiveness of new biologicals for the treatment of allergic diseases relates to the eicosanoids.

• Re-assessment of the effects of prostanoids in allergic and asthmatic reactions in humans by targeted intervention studies with selective inhibitors of receptors or tissue-specific synthases.

• Development and testing of novel treatment modalities targeting lipid mediators (eicosanoids) and their receptors.

MiSo has received research grants from the Swiss National Science Foundation, GlaxoSmithKline, Novartis, and AstraZeneca speaker fee.

ZD acted as a director respiratory/allergy for QPS-NL (2012-2020);

she has received consulting fees from ALK, Antabio, GSK, Sanofi- Other authors do not have any COI to declare.

Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I

Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma

Viruses and bacteria in acute asthma exacerbations-a GA(2) LEN-DARE systematic review

The first wheezing episode: respiratory virus etiology, atopic characteristics, and illness severity

Human bocaviruses and paediatric infections

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets

Th2-type cytokine-induced mucus metaplasia decreases susceptibility of human bronchial epithelium to rhinovirus infection

Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from nonatopic subjects

Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells

Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production

Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers

Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology

Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation

Control of RSVinduced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent

The resolution of inflammation

Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages

Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition

Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice

Dexamethasone, proresolving lipid mediators and resolution of inflammation in COVID-19

NSAIDs and COVID-19: a systematic review and meta-analysis

Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats

Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium

Activation of COX-2/PGE2 promotes sapovirus replication via the inhibition of nitric oxide production

Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice

The roles of lipids in SARS-CoV-2 viral replication and the host immune response

Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular Cyclic AMP in human macrophages

Virus-induced inflammasome activation is suppressed by prostaglandin D 2 /DP1 signaling

Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: a systematic review and meta-analysis of adjusted effect estimates

Immunology of COVID-19: mechanisms, clinical outcome, diagnostics, and perspectives-a report of the European Academy of Allergy and Clinical Immunology (EAACI)

Non-steroidal antiinflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection

High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients

Cutting edge: severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome, resulting in dysregulation of eicosanoid immune mediators

Influence of daily aspirin therapy on ACE2 expression and function-implications for SARS-CoV-2 and patients with aspirin-exacerbated respiratory disease

Antiviral properties of the NSAID drug naproxen targeting the nucleoprotein of SARS-CoV-2 coronavirus

Acetaminophen): mechanisms of action

The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings

NSAID use and clinical outcomes in COVID-19 patients: A 38-center retrospective cohort study. medRxiv

Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients

Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study

Non-steroidal antiinflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study

Non-steroidal antiinflammatory agent use may not be associated with mortality of coronavirus disease 19

Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease

Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends

Montelukast in the treatment of asthma and beyond

Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism

Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity

CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors

Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists

Pranlukast inhibits NF-kappa B activation in human monocytes/ macrophages and T cells

Pranlukast inhibits NF-kappaB activation and MUC2 gene expression in cultured human epithelial cells

The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinylleukotrienes receptor

Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast

ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4)

Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma

Characterization of the human cysteinyl leukotriene CysLT 1 receptor

Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma

A placebo-controlled, doseranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor

Pharmacogenetic association between ALOX5 promoter genotype and the response to antiasthma treatment

Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response

Antileukotriene agents for the treatment of lung disease

Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation. a clinical observational study

Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma

Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma

Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group

Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial

Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial

Montelukast reduces asthma exacerbations in 2-to 5-year-old children with intermittent asthma

Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients

Leukotriene antagonists as first-line or add-on asthma-controller therapy

Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma

Leukotriene E(4) in urine in patients with asthma and COPD-the effect of smoking habit

Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma

Effect of montelukast for treatment of asthma in cigarette smokers

Body mass index is associated with leukotriene inflammation in asthmatics

Influence of body mass index on the response to asthma controller agents

Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) -classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*

Sex-biased eicosanoid biology: impact for sex differences in inflammation and consequences for pharmacotherapy

ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma

Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males

Progesterone rapidly down-regulates the biosynthesis of 5-lipoxygenase products in human primary monocytes

Leukotriene-mediated sex dimorphism in murine asthma-like features during allergen sensitization

Impact of androgens on inflammation-related lipid mediator biosynthesis in innate immune cells

Montelukast improves symptoms and lung function in asthmatic women compared with men

Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Risk factors for severe and critically ill COVID-19 patients: a review

Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19

As a potential treatment of COVID-19: montelukast

The leukotriene receptor antagonist montelukast as a potential COVID-19 therapeutic

Montelukast drug may improve COVID-19 prognosis: a review of evidence

Montelukast protects against bradykinin-induced bronchospasm

Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes

Cytokine storm

Direct airway injury results in elevated levels of sulfidopeptide leukotrienes, detectable in airway secretions

Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms

Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules

Leukotriene receptor antagonist pranlukast suppresses eosinophil infiltration and cytokine production in human nasal mucosa of perennial allergic rhinitis

The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast

Montelukast in hospitalized patients diagnosed with COVID-19

Montelukast's ability to fight COVID-19 infection

Montelukast use decreases cardiovascular events in asthmatics

Leukotriene modifiers as potential therapeutics for cardiovascular disease

Montelukast inhibits platelet activation induced by plasma from COVID-19 patients

A novel strategy to mitigate the hyperinflammatory response to COVID-19 by targeting leukotrienes

Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

The role of prostaglandins in allergic lung inflammation and asthma

Impact of highaltitude therapy on type-2 immune responses in asthma patients

Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy

Targeting lipid mediators in asthma: time for reappraisal

The impact of the prostaglandin D(2) receptor 2 and its downstream effects on the pathophysiology of asthma

Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459

Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics

Prostaglandin D(2) receptors in human mast cells

Cholinergic-mediated bronchoconstriction induced by prostaglandin D2, its initial metabolite 9 alpha,11 beta-PGF2, and PGF2 alpha in asthma

The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo

Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo-and active-referenced studies

DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment

Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation

The impact of the prostaglandin D2 receptor 2 and its downstream effects on the pathophysiology of asthma

Cyclooxygenase-2/prostaglandin D2/CRTH2 pathway mediates double-stranded RNAinduced enhancement of allergic airway inflammation

PGD2/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFNlambda production

Prostaglandin D2 as a mediator of lymphopenia and a therapeutic target in COVID-19 disease

Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor

An introduction to the endogenous cannabinoid system

New approaches and challenges to targeting the endocannabinoid system

Towards the use of cannabinoids as antitumour agents

Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites

Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders

Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease

COX-2-derived endocannabinoid metabolites as novel inflammatory mediators

NSAIDs: eNdocannabinoid stimulating antiinflammatory drugs?

The role of cannabinoids in allergic diseases: Collegium Internationale Allergologicum (CIA) update 2020

Cannabinoid receptor 1 controls human mucosal-type mast cell degranulation and maturation in situ

Endocannabinoids limit excessive mast cell maturation and activation in human skin

Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors

Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma

Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice

Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs

Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis

Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model

Selective cannabinoid receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model

Antiinflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis

Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis

Protective role of palmitoylethanolamide in contact allergic dermatitis

The effect of cannabinoids on dinitrofluorobenzene-induced experimental asthma in mice

The cannabinoid WIN55212-2 restores rhinovirus-induced epithelial barrier disruption

Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprograming

The potential of cannabidiol in the COVID-19 pandemic

Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients

Cannabinoid receptor type 2: a possible target in SARS-CoV-2 (CoV-19) infection?

Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice

The cannabinoid receptor-2 is involved in allergic inflammation

CB2 receptors regulate natural killer cells that limit allergic airway inflammation in a murine model of asthma

The expression of cannabinoid receptor 1 is significantly increased in atopic patients

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebocontrolled, parallel-group phase 3 trials

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials

The role of type 2 inflammation in the pathogenesis of asthma exacerbations

Biologics for chronic rhinosinusitis with nasal polyps

ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions

Allergy in severe asthma

Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype

A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects

Expanding roles for leukotrienes in airway inflammation

The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma

Comparable actions of omalizumab on mast cells and basophils

Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis

Efficacy and safety of antagonists for chemoattractant receptor-homologous molecule expressed on Th2 cells in adult patients with asthma: a meta-analysis and systematic review

Leukotriene receptor antagonists in virus-induced wheezing : evidence to date

Chronic rhinosinusitis with nasal polyps and asthma

Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper

Subphenotypes of nonsteroidal antiinflammatory diseaseexacerbated respiratory disease identified by latent class analysis

Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirinsensitive asthmatic subjects

Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma

Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirinintolerant asthma

Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma

Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirininduced asthma

Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirinintolerant compared with aspirin-tolerant asthma

Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease

Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs

The development of COX2 inhibitors

NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs

COX-2 and beyond: approaches to prostaglandin inhibition in human disease

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

Progress in understanding hypersensitivity reactions to nonsteroidal antiinflammatory drugs

Recent developments and highlights in biomarkers in allergic diseases and asthma

Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients

Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs

Clinical course and urinary eicosanoids in patients with aspirininduced urticaria followed up for 4 years

Polymorphisms of cyclooxygenases and 5-lipo-oxygenase-activating protein are associated with chronic spontaneous urticaria and urinary leukotriene E4

Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti-inflammatory drug-induced urticaria

Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients

Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma

A possible role for cysteinyl-leukotrienes in non-ionic contrast media induced adverse reactions

Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator release

Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs

Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

Regulation of cyclooxygenase activity by metamizol

Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group

Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)

Effects of extendedrelease niacin with laropiprant in high-risk patients

Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19